Agile Therapeutics, Inc.
AGRX
OTC PK
| Weiss Ratings | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.19 | |||
| Price History | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -- | |||
| 52-Week Low % Change | -- | |||
| Price | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.63 | |||
| 52-Week Low Price | $0.20 | |||
| 52-Week Low Price (Date) | Mar 26, 2024 | |||
| 52-Week High Price (Date) | Sep 01, 2023 | |||
| Valuation | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | -- | |||
| Enterprise Value | 7.87M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.24 | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.48 | |||
| Price/Book (Q) | -0.48 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | -- | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 6.86M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 609 683 1880 | |||
| Address | 500 College Road East Princeton, NJ 08540 | |||
| Website | www.agiletherapeutics.com | |||
| Country | United States | |||
| Year Founded | 1997 | |||
| Profitability | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -62.84% | |||
| Profit Margin | -73.52% | |||
| Management Effectiveness | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -61.54% | |||
| Return on Equity | -- | |||
| Income Statement | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 21.57M | |||
| Total Revenue (TTM) | 21.57M | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 13.72M | |||
| EBITDA (TTM) | -13.15M | |||
| EBIT (TTM) | -13.56M | |||
| Net Income (TTM) | -15.86M | |||
| Net Income Avl. to Common (TTM) | -15.86M | |||
| Total Revenue Growth (Q YOY) | 1.33% | |||
| Earnings Growth (Q YOY) | -211.68% | |||
| EPS Diluted (TTM) | -3.24 | |||
| EPS Diluted Growth (Q YOY) | 19.54% | |||
| Balance Sheet | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.85M | |||
| Cash Per Share (Q) | $0.42 | |||
| Total Current Assets (Q) | 14.44M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -21.91M | |||
| Current Ratio (Q) | 0.551 | |||
| Book Value Per Share (Q) | -$3.17 | |||
| Total Assets (Q) | 14.96M | |||
| Total Current Liabilities (Q) | 26.23M | |||
| Total Debt (Q) | 289.00K | |||
| Total Liabilities (Q) | 36.88M | |||
| Total Common Equity (Q) | -21.91M | |||
| Cash Flow | AGRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 1.77M | |||
| Net Change in Cash (TTM) | 64.00K | |||
| Levered Free Cash Flow (TTM) | 3.95M | |||
| Cash from Operations (TTM) | -1.71M | |||
